Japan Medical Dynamic Marketing (7600) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter was characterized by declining revenue and earnings, as both the Japan and U.S. segments posted double-digit revenue declines and operating income fell from a profit in the previous year to a loss. Revenue was ¥5.32B (¥5.92B in the previous year, YoY -10.0%), Operating Income was ¥-0.53B (¥0.15B in the previous year), Ordinary Income was ¥-0.54B (¥0.11B in the previous year), and Net Income attributable to the consolidated group was ¥-0.42B (¥0.07B in the previous year, YoY -715.9%). The gross margin deteriorated by 6.5pt to 55.1% from 61.6% in the previous year, while the SG&A ratio rose by 5.8pt to 64.9%, accelerating the deterioration in earnings due to insufficient fixed-cost absorption amid declining revenue. Earnings per share were ¥-15.85 (based on net income attributable to owners of the parent; ¥+2.50 in the previous year).

Factors Affecting Results

【Revenue】Revenue was ¥5.32B, down -10.0% year on year, with both the Japan segment (¥2.77B, -13.4%) and U.S. segment (¥3.62B, -11.2%) posting double-digit revenue declines. Demand appeared weak across regions, indicating a broad-based revenue decline rather than a temporary factor limited to a specific region.

【Profitability】The gross margin deteriorated to 55.1% (61.6% in the previous year, -6.5pt), suggesting lower profitability due to a combination of pricing, product mix, and cost factors. SG&A expenses were ¥3.46B, approximately flat year on year (¥3.50B in the previous year); however, the SG&A ratio rose to 64.9% (59.1% in the previous year, +5.8pt) as revenue declined, and insufficient fixed-cost absorption resulted in an Operating Loss of ¥-0.53B. In non-operating items, a foreign exchange gain of ¥0.06B was generated, but this was almost entirely offset by ¥0.06B in interest expense, resulting in Ordinary Loss of ¥-0.54B. Extraordinary losses, including losses on disposal of fixed assets, were minor at ¥0.01B, indicating limited impact from temporary factors. Net loss was reduced to ¥-0.42B as income taxes and other taxes were ¥-0.13B due to tax effects. The company recorded lower revenue and earnings as operating leverage worked in reverse.

Segment Analysis

Both the Japan and U.S. segments fell into the red on an operating basis, indicating that the deterioration in profitability extended across both regions. The U.S. segment generated revenue of ¥3.62B (down -11.2% year on year) and an Operating Loss of ¥-0.50B (from ¥+0.09B in the previous year, YoY -633.2%), with a -13.7% operating margin, making it the primary driver of the company-wide loss. The Japan segment also posted revenue of ¥2.77B (-13.4%) and an Operating Loss of ¥-0.03B (from ¥+0.08B in the previous year, YoY -133.0%), resulting in a -1.0% operating margin and a marginal move into the red. The U.S. segment accounted for the majority of the consolidated Operating Loss of ¥-0.53B, and the company’s high dependence on the U.S. business represents a source of earnings volatility risk by region.

Key Financial Metrics

【Profitability】The Operating Margin deteriorated significantly to -9.9% (from +2.5% in the previous year), while the gross margin declined to 55.1% (61.6% in the previous year), and ROE also turned negative at -1.7%. 【Cash Quality】Inventories were ¥13.59B, representing 38.4% of total assets. Together with accounts receivable of ¥4.60B, this indicates a high level of working capital and a structure prone to divergence between earnings and cash generation. 【Investment Efficiency】Research and development expenses were ¥0.27B (5.1% of revenue, up from 3.7% in the previous year), indicating that the level of development investment has been maintained. 【Financial Soundness】The Equity Ratio remained high at 70.2% (71.2% in the previous year), while cash and deposits declined by -17.5% from ¥3.11B in the previous year to ¥2.56B, and short-term borrowings increased by +17.1% from ¥4.89B in the previous year to ¥5.72B.

Cash Flow Analysis

Because cash flow statement figures have not been disclosed, funding trends are assessed using key balance sheet items. Cash and deposits were ¥2.56B, down ¥0.54B (-17.5%) from ¥3.11B in the same period of the previous year, suggesting that the operating loss and working capital burden placed pressure on liquidity. Inventories remained elevated at ¥13.59B, up +3.8% year on year. Accounts receivable declined somewhat to ¥4.60B, down -12.2% year on year; however, delays in converting inventory into cash may have weighed on cash generation. Meanwhile, short-term borrowings increased +17.1% to ¥5.72B from ¥4.89B in the previous year, indicating a growing reliance on short-term borrowings to fund working capital. Long-term borrowings were ¥0.70B (¥0.77B in the previous year), broadly flat, suggesting a shift toward short-term financing.

Quality of Earnings

The loss for the current period resulted not from extraordinary items but from deterioration in recurring operating earnings, indicating structurally lower earnings power from a quality-of-earnings perspective. Extraordinary losses, including losses on disposal of fixed assets, were limited to ¥0.01B and had a minor impact on net loss. Non-operating income of ¥0.07B consisted primarily of a ¥0.06B foreign exchange gain and represented only 1.3% of revenue. As this was nearly offset by ¥0.08B in non-operating expenses, primarily ¥0.06B in interest expense, its impact on Ordinary Income was limited. Income taxes and other taxes were ¥-0.13B, reducing Net Loss to approximately ¥-0.42B compared with Profit Before Tax of ¥-0.55B; however, the underlying operating loss excluding tax effects has not improved. The high levels of accounts receivable and inventories suggest a condition prone to divergence between earnings and cash generation (accruals), warranting attention to the speed at which earnings are converted into cash.

Earnings Forecast and Guidance

The progress rate against the full-year plan was 21.0% for revenue (¥5.32B/¥25.37B), below the 25% implied by a simple time-elapsed basis. Against the full-year Operating Income plan of ¥0.43B, the company had already recorded an Operating Loss of ¥-0.53B as of Q1, making substantial earnings improvement over the remaining three quarters a prerequisite for achieving the plan. Similarly, against the Ordinary Income plan of ¥0.14B, a Q1 loss of ¥-0.54B had already been recorded, indicating significant underperformance. As of the current quarter, the company had made no revisions to either its earnings forecast or dividend forecast, and its full-year plan remained unchanged.

Shareholder Returns

The annual dividend forecast is ¥0, maintaining the policy of no dividend for the second consecutive year. As the company recorded a quarterly net loss (Net Income of ¥-0.42B), the Payout Ratio was not calculable, indicating a conservative shareholder-return policy that prioritizes financial soundness.

Risk Factors

1. Deterioration in profitability of the Americas business: The U.S. segment generated revenue of ¥3.62B (-11.2%) and an Operating Loss of ¥-0.50B (YoY -633.2%), with a -13.7% operating margin, making it the primary driver of the company-wide loss. The high dependence on this region, which accounts for more than half of consolidated revenue, represents a risk.

2. Working capital accumulation and liquidity management: While inventories of ¥13.59B (38.4% of total assets) and accounts receivable of ¥4.60B remained high, cash and deposits declined by -17.5% year on year to ¥2.56B, while short-term borrowings increased +17.1% to ¥5.72B, indicating growing dependence on short-term financing.

3. Reduced capacity to absorb interest expense due to deteriorating profitability: Interest expense of ¥0.06B was incurred against an Operating Loss of ¥-0.53B, indicating that the company is unable to cover its interest burden through its core business. Ordinary Loss was also ¥-0.54B, and a further decline in the capacity to absorb financial costs is a concern if earnings recovery is delayed.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability was substantially below the industry median, with both the Operating Margin and Net Profit Margin ranking in the lower range of the industry.

Growth and Capital Efficiency

Growth also fell substantially below the industry median, highlighting the company’s pronounced gap with other companies in the industry that are on a revenue growth trajectory.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Both the Japan and U.S. segments simultaneously experienced declining revenue and operating losses, causing the Operating Margin to fall by approximately 12pt from +2.5% in the previous year to -9.9%. The deterioration in earnings power across regions suggests a structural issue rather than a temporary factor.

2. Against the full-year Operating Income plan of ¥0.43B, an Operating Loss of ¥-0.53B had already been recorded in Q1, while the revenue progress rate remained at only 21.0%. The need for substantial earnings improvement in the second half of the fiscal year to achieve the plan is a key point in assessing the feasibility of the full-year outlook.

3. Inventories accounted for 38.4% of total assets, and working capital remained high together with accounts receivable. Cash and deposits declined while short-term borrowings increased, making the reduction of working capital a key factor in restoring future cash-generation capacity.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥686–¥727 at Cost of Equity ±1%, and ¥698–¥711 at ω±0.1.

Notes:

• Due to tax burdens, acquisition-related expenses, non-controlling interests, and other factors, Net Income is significantly compressed relative to Operating Income (Net Income ÷ Operating Income 14%). This value reflects that compression at face value; if the factors are temporary, normalized earnings power may be higher.
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used; there is a timing difference relative to the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value is not a forecast or guarantee of future share prices)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional advisor as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a materially weak start, with a revenue decline translating into a substantial operating and net loss. Revenue fell 10.0% YoY to ¥5.33bn. Operating income deteriorated from a ¥0.15bn profit to a ¥0.53bn loss. Net income attributable to owners deteriorated from a ¥0.07bn profit to a ¥0.42bn loss. The gross margin fell to 55.1% from 61.6% a year earlier, a contraction of approximately 659bp. SG&A expenses declined 1.2% YoY to ¥3.46bn, but the reduction was far smaller than the revenue decline. Consequently, SG&A rose to 64.9% of revenue from 59.1%, an approximately 584bp adverse shift. The operating margin therefore deteriorated by approximately 1,242bp to -9.9%. Japan segment revenue declined 13.5% YoY to ¥2.77bn and recorded a ¥0.28bn segment loss. US segment external revenue declined 6.0% to ¥2.56bn, while its segment loss widened sharply to ¥4.97bn and accounted for most of the consolidated operating loss. Gross profit declined 19.7% YoY to ¥2.93bn, indicating that lower sales were compounded by material gross-margin pressure. FX gains of ¥0.64bn substantially offset ¥0.60bn of interest expense, but were insufficient to prevent an ordinary loss of ¥0.54bn. The tax benefit of ¥0.13bn reduced the net loss, but does not alter the underlying operating weakness. Balance-sheet liquidity remains ample on the current ratio of 299.4% and quick ratio of 132.8%, although the asset mix is heavily concentrated in inventory. Short-term borrowings are the principal funding issue, representing 89.1% of interest-bearing debt, while cash covers only 0.45x of short-term borrowings. Management retained its full-year forecast of ¥25.37bn in sales, ¥0.43bn in operating income and ¥0.06bn in profit attributable to owners, which requires a pronounced recovery from the Q1 loss. The investment focus is therefore on the timing and credibility of US profitability recovery, gross-margin normalization, inventory monetization, and refinancing management.

Profitability Analysis

Annualized DuPont ROE is -6.7%, comprising a -7.8% net profit margin, 0.602x asset turnover, and 1.43x financial leverage. The primary negative driver is the net margin, rather than aggressive leverage: financial leverage remains moderate and asset turnover is constrained by the large inventory base. The operating margin moved to -9.9% from approximately 2.5% in the prior-year quarter, reflecting both a 10.0% revenue decline and gross-margin compression. Gross profit fell ¥0.72bn, whereas SG&A declined by only ¥0.04bn, demonstrating unfavorable operating leverage. Salaries and allowances increased 2.0% YoY to ¥1.07bn, and R&D expense increased 25.1% to ¥0.27bn; these investments may support product competitiveness but intensified the near-term earnings shortfall. Commission expense declined 7.7% to ¥0.84bn, providing only limited offset to lower gross profit. The US segment was the key earnings drag, with a segment margin of approximately -19.4% on external revenue, versus a positive margin in the comparable quarter. Japan, the core business by current-period segment profit contribution because its loss was considerably smaller than that of the US, also shifted to a loss, confirming that pressure is not confined to one geography. The reported annualized ROIC of -5.6% is below the 5% warning threshold and indicates that operating assets are currently not earning their cost of capital. The tax burden of 0.759 is mechanically supportive due to the loss-related tax benefit, while the interest burden of 1.044x reflects the fact that non-operating FX gains slightly exceeded net interest and other non-operating costs. The ¥0.64bn FX gain was larger than the ¥0.53bn operating loss, emphasizing that ordinary earnings would have been weaker without currency-related income. Profitability recovery depends on restoring gross margin and absorbing the fixed elements of SG&A through renewed revenue growth, particularly in the US operation.

Growth Assessment

Revenue contraction was broad-based: Japan declined 13.5% YoY and the US declined 6.0% YoY on an external-sales basis. The comparatively smaller US sales decline did not protect earnings, as the US segment moved from a ¥0.93bn profit to a ¥4.97bn loss. This divergence suggests that current growth quality is weak, with margin and cost absorption more important than sales volume alone. Consolidated gross margin compression indicates unfavorable pricing, product mix, procurement, or inventory-cost absorption dynamics. The FY2027 sales forecast of ¥25.37bn implies a 6.1% full-year increase, despite the 10.0% Q1 decline. Q1 sales represent 21.0% of the full-year forecast, only 4.0 percentage points below the standard 25% first-quarter progress rate and not, by itself, an exceptional seasonal deviation. However, the operating loss of ¥0.53bn contrasts with the ¥0.43bn full-year operating-profit target; the company must generate approximately ¥0.96bn of operating profit during the remaining nine months. Q1 ordinary income and profit attributable to owners are also below the full-year targets of ¥0.14bn and ¥0.06bn, respectively, requiring a turnaround rather than incremental improvement. The retained forecast, with no revision announced, raises the importance of evidence that gross margin, US segment profitability, and sales momentum improve from Q2 onward. R&D spending was 5.1% of Q1 revenue, a meaningful level for a medical-device manufacturer and potentially supportive of product renewal, though it adds to near-term cost pressure. Revenue sustainability should be assessed through the ability to convert the very large finished-goods inventory base into sales without additional discounting or margin erosion.

Financial Health

Liquidity ratios are strong in headline terms, with a current ratio of 299.4%, a quick ratio of 132.8%, and working capital of ¥16.27bn. Accordingly, there is no current-ratio warning: current assets substantially exceed current liabilities. However, inventory represents 38.4% of total assets and 55.6% of current assets, meaning that headline liquidity is materially dependent on inventory realization. Cash and deposits fell 17.5% YoY to ¥2.56bn, while short-term loans increased 17.1% to ¥5.72bn. Interest-bearing debt totaled ¥6.43bn, including ¥5.72bn of short-term loans and ¥0.70bn of long-term loans. The 89.1% short-term debt ratio is a refinancing-risk alert because a substantial portion of funding must be rolled over or repaid within one year. Cash-to-short-term-debt is only 0.45x, below the 0.5x alert level, so immediate cash alone does not cover short-term borrowings. This maturity mismatch is mitigated by receivables of ¥4.60bn and inventory of ¥13.59bn, but the unusually long working-capital cycle makes the conversion timing important. Debt-to-equity is 0.43x and debt-to-capital is 20.6%, both conservative relative to stated solvency benchmarks and materially below levels that would indicate excessive balance-sheet leverage. Total equity declined 2.4% YoY to ¥24.83bn, principally alongside lower retained earnings, while the equity ratio remained high at 70.1%. Interest coverage was -8.78x because EBIT was negative; this is a debt-service alert despite the moderate absolute debt burden. Net defined-benefit liability of ¥1.39bn and asset-retirement obligations of ¥0.03bn are recognized non-debt obligations within the liability structure.

Cash Flow Quality

The operating loss means that near-term cash generation should be assessed primarily through working-capital behavior and inventory conversion. Accounts receivable decreased 12.2% YoY to ¥4.60bn, which is favorable in absolute balance-sheet terms, but reported annualized DSO remains elevated at 79 days and exceeds the 60-day quality-alert threshold. Finished-goods inventory increased 3.8% YoY to ¥13.59bn, while raw materials rose 5.1% to ¥2.76bn and work in process declined 10.5% to ¥0.40bn. Finished goods dominate the disclosed inventory composition, making demand realization, potential obsolescence, and gross-margin protection central cash-flow considerations. The reported annualized inventory-days alerts of 518 days and 639 days are both far above relevant manufacturing benchmarks, indicating exceptionally slow inventory turnover under the respective reported calculation bases. The reported annualized cash-conversion-cycle alert of 673 days is correspondingly well above the 120-day warning threshold. Trade payables declined 15.9% YoY to ¥1.17bn, which reduces supplier financing and can lengthen the cash conversion cycle when inventory remains elevated. These working-capital metrics are a material earnings-quality concern because cash tied up in inventory may delay the conversion of future sales into liquidity. The reported high DSO, high inventory days, and long cash-conversion-cycle alerts point to operational cash pressure rather than a conventional leverage problem. Inventory reduction without price concessions or write-downs would be a positive catalyst for both cash flow and profitability. Conversely, continued finished-goods accumulation would heighten the risk of discounting, provisions, or future inventory valuation losses.

Dividend Sustainability

The full-year dividend forecast is ¥17.00 per share, unchanged under the disclosed revision information. Against forecast EPS of ¥2.28, the implied dividend payout ratio is approximately 746%, far above the 60% sustainability benchmark and above 100%. Based on the forecast profit attributable to owners of ¥0.06bn, the projected cash dividend requirement is approximately ¥0.45bn using average shares, substantially exceeding forecast earnings. Q1 EPS was a loss of ¥15.85, so current-period earnings do not provide dividend coverage. The strong equity base and positive working capital provide balance-sheet capacity in the near term, but this is not equivalent to recurring earnings coverage. The sustainability of the stated dividend depends on a much stronger second-half recovery, use of accumulated retained earnings, or both. Retained earnings remain sizeable at ¥14.75bn, but declined 5.6% YoY. Dividend policy should be monitored alongside cash balances, short-term debt rollovers, inventory conversion, and the delivery of the retained full-year earnings target. No share buyback information is reported, so the analysis is confined to the dividend payout ratio rather than a total return ratio.

Risk Assessment

Business risks include US profitability risk: the US segment generated a ¥4.97bn loss after a ¥0.93bn profit in the prior-year quarter, making its recovery the largest determinant of consolidated earnings normalization., Gross-margin risk: consolidated gross margin declined approximately 659bp to 55.1%, exposing earnings to pricing, product mix, procurement cost, and production-cost absorption pressure., Medical-device inventory risk: finished goods of ¥13.59bn dominate the inventory balance, creating risks of slow-moving stock, obsolescence, discounting, and valuation losses if demand does not recover., Foreign-exchange risk: Q1 FX gains of ¥0.64bn materially supported ordinary income; future currency movements can therefore add volatility to earnings., Innovation and regulatory execution risk: R&D expense rose 25.1% YoY to ¥0.27bn, and the return on this investment depends on successful product development, approvals, and commercial adoption..

Financial risks include Debt-service risk: interest coverage of -8.78x is below the 2.0x warning level because EBIT was negative; sustained losses would weaken capacity to service interest from operating earnings., Refinancing risk: 89.1% of interest-bearing debt is short term, requiring continued access to bank funding or working-capital monetization., Cash coverage risk: cash-to-short-term-debt of 0.45x is below the 0.5x alert threshold, despite healthy current and quick ratios., Working-capital risk: reported annualized DSO of 79 days, inventory days of 518-639 days, and cash conversion cycle of 673 days imply cash is tied up for an extended period., Capital-efficiency risk: reported annualized ROIC of -5.6% and ROE of -6.7% indicate negative current returns on the capital employed..

Key concerns include Highest priority: whether the US segment can reverse its Q1 loss without requiring further price concessions or incremental fixed-cost spending., High priority: whether finished-goods inventory can be reduced while preserving gross margin and avoiding write-downs., High priority: whether the company can deliver the ¥0.43bn full-year operating-profit forecast after a ¥0.53bn Q1 operating loss., Moderate priority: rising short-term loans combined with lower cash, even though total leverage remains conservative., Moderate priority: the ¥17 per-share dividend forecast appears unsupported by forecast earnings and requires close monitoring of capital-allocation discipline..

Investment Implications

Key takeaways include Q1 earnings weakened sharply, with operating margin falling to -9.9% and net margin to -7.8%., The US segment was the principal earnings drag, but Japan also moved into a loss, indicating broad-based operating pressure., The company retains a robust equity ratio of 70.1% and healthy current and quick ratios, limiting immediate balance-sheet stress., The risk profile is elevated by negative interest coverage, a short-term debt ratio of 89.1%, cash coverage of only 0.45x of short-term debt, and very slow reported inventory turnover., The retained full-year forecast requires a substantial Q2-Q4 operating recovery, while the forecast dividend implies a payout ratio of about 746%..

Metrics to watch include US segment revenue, segment margin, and the scale of its operating-loss recovery, Consolidated gross margin and SG&A-to-sales ratio, Finished-goods inventory balance, reported annualized inventory days, and any inventory valuation charges, Annualized DSO, cash conversion cycle, and trade-payables trend, Cash balance, short-term loan balance, cash-to-short-term-debt ratio, and borrowing rollover terms, Progress toward the ¥25.37bn sales and ¥0.43bn operating-income full-year forecasts, Dividend policy relative to forecast earnings and retained earnings.

Regarding relative positioning, The company combines a strong equity-funded balance sheet and high reported current liquidity with weak current operating returns and unusually inventory-intensive working capital. Relative positioning is therefore likely to depend less on leverage capacity and more on the speed of US operational recovery, gross-margin restoration, and inventory-to-cash conversion.